stockrowBio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.8%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) Free cash flow
Bio-Rad Laboratories, Inc.'s free cash flow for fiscal 2025 was $374.7M, up 29.3% from $289.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $329.1M. Over the past ten years it has ranged from −$10.9M (fiscal 2017) to $535.8M (fiscal 2021); the current reading is higher than 82% of that period. Free cash flow has risen for 3 consecutive fiscal years. Bio-Rad Laboratories, Inc. ranks 13th of 149 Medical Devices companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $374.7M | 29.34% |
| FY2024 | $289.7M | 32.65% |
| FY2023 | $218.4M | 171.98% |
| FY2022 | $80.3M | (85.01%) |
| FY2021 | $535.8M | 11.64% |
| FY2020 | $479.9M | 30.29% |
| FY2019 | $368.3M | 130.22% |
| FY2018 | $160.0M | — |
| FY2017 | −$10.9M | — |
| FY2016 | $74.9M | 2.71% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $65.2M | (2.10%) |
| Jun 2026 | $66.6M | (14.83%) |
| Mar 2026 | $78.2M | (34.34%) |
| Dec 2025 | $119.1M | 33.52% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| GMED Globus Medical, Inc. compare | $766.6M |
| BIO.B Bio-Rad Laboratories, Inc. | $468.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $468.1M |
| PODD Insulet Corporation compare | $260.0M |
| BRKR Bruker Corporation compare | $244.7M |
| PEN Penumbra, Inc. compare | $200.3M |
| TXG 10x Genomics compare | $121.4M |
| GKOS Glaukos Corporation compare | $36.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement